Treatment of resistant rheumatoid arthritis with minocycline: An open study

P. Langevitz*, I. Bank, D. Zemer, M. Book, M. Pras

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


In a 48-week open trial, 18 patients with active rheumatoid arthritis (RA), resistant to second line agents, received 200 mg minocycline daily. Twelve patients completed 48 weeks of therapy. Statistically significant improvement was noted in almost all variables of disease activity. Three patients discontinued therapy because of lack of improvement, 2 patients because of side effects and one patient was lost to follow-up. Cytofluorographic analysis revealed a significant decrease in expression of a T cell activation antigen (gp 26). Our data suggest that minocycline could be a useful therapeutic agent in RA.

Original languageEnglish
Pages (from-to)1502-1504
Number of pages3
JournalJournal of Rheumatology
Issue number10
StatePublished - 1992
Externally publishedYes


  • T cells
  • minocycline
  • rheumatoid arthritis


Dive into the research topics of 'Treatment of resistant rheumatoid arthritis with minocycline: An open study'. Together they form a unique fingerprint.

Cite this